Cargando…
Clinical Experience and Recent Advances in the Development of Listeria-Based Tumor Immunotherapies
The promise of tumor immunotherapy to significantly improve survival in patients who are refractory to long-standing therapies, such as chemotherapy and radiation, is now being realized. While immune checkpoint inhibitors that target PD-1 and CTLA-4 are leading the charge in clinical efficacy, there...
Autores principales: | Oladejo, Mariam, Paterson, Yvonne, Wood, Laurence M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081050/ https://www.ncbi.nlm.nih.gov/pubmed/33936058 http://dx.doi.org/10.3389/fimmu.2021.642316 |
Ejemplares similares
-
Listeria-based immunotherapy directed against CD105 exerts anti-angiogenic and anti-tumor efficacy in renal cell carcinoma
por: Oladejo, Mariam, et al.
Publicado: (2022) -
Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy
por: Wood, Laurence M., et al.
Publicado: (2014) -
Listeria monocytogenes: a promising vector for tumor immunotherapy
por: Ding, Yi-Dan, et al.
Publicado: (2023) -
Interferon γ-induced intratumoral expression of CXCL9 alters the local distribution of T cells following immunotherapy with Listeria monocytogenes
por: Guirnalda, Patrick, et al.
Publicado: (2013) -
Recent advances in exosome-based immunotherapy applied to cancer
por: Xie, Jindong, et al.
Publicado: (2023)